Table 3.
Effect of interventions on echocardiographic indices
| Placebo | Fenofibrate | CoQ | Combination | P for interaction | Fenofibrate main effect | P | CoQ main effect | P | |
|---|---|---|---|---|---|---|---|---|---|
| n | 20 | 16 | 16 | 17 | |||||
| E′ (cm/s) | |||||||||
| Baseline | 8.4 ± 0.3 | 8.5 ± 0.3 | 9.2 ± 0.4 | 8.6 ± 0.4 | |||||
| End | 8.6 ± 0.3 | 8.1 ± 0.3 | 8.9 ± 0.4 | 8.7 ± 0.4 | 0.094 | −0.1 ± 0.2 | 0.539 | 0.1 ± 0.2 | 0.698 |
| E/A | |||||||||
| Baseline | 0.82 ± 0.03 | 0.83 ± 0.03 | 0.90 ± 0.04 | 0.91 ± 0.10 | |||||
| End | 0.83 ± 0.03 | 0.85 ± 0.03 | 0.92 ± 0.04 | 0.99 ± 0.11 | 0.262 | 0.04 ± 0.02 | 0.112 | 0.04 ± 0.02 | 0.129 |
| DT (ms) | |||||||||
| Baseline | 218 ± 6 | 233 ± 7 | 215 ± 8 | 215 ± 7 | |||||
| End | 215 ± 6 | 220 ± 9 | 206 ± 7 | 212 ± 6 | 0.376 | 2 ± 6 | 0.779 | −2 ± 6 | 0.737 |
| IVRT (ms) | |||||||||
| Baseline | 106 ± 3 | 108 ± 1 | 108 ± 2 | 109 ± 2 | |||||
| End | 108 ± 2 | 112 ± 3 | 109 ± 3 | 111 ± 2 | 0.655 | 2 ± 2 | 0.338 | −1 ± 2 | 0.530 |
| Vp (cm/s) | |||||||||
| Baseline | 41.5 ± 1.4 | 42.0 ± 1.3 | 44.1 ± 2.0 | 41.9 ± 1.7 | |||||
| End | 40.9 ± 1.2 | 44.4 ± 1.8 | 42.9 ± 1.7 | 42.9 ± 1.9 | 0.531 | 2.4 ± 1.0 | 0.020 | −0.8 ± 1.0 | 0.451 |
| E/E′ | |||||||||
| Baseline | 7.7 ± 0.3 | 8.0 ± 0.4 | 7.8 ± 0.5 | 7.9 ± 0.5 | |||||
| End | 7.6 ± 0.3 | 8.5 ± 0.3 | 8.3 ± 0.5 | 8.6 ± 0.5 | 0.345 | 0.5 ± 0.3 | 0.078 | 0.4 ± 0.3 | 0.130 |
| E/Vp | |||||||||
| Baseline | 1.56 ± 0.07 | 1.60 ± 0.06 | 1.59 ± 0.05 | 1.60 ± 0.08 | |||||
| End | 1.59 ± 0.06 | 1.56 ± 0.05 | 1.70 ± 0.07 | 1.73 ± 0.07 | 0.367 | 0.00 ± 0.05 | 0.940 | 0.12 ± 0.05 | 0.007 |
| PV S/D | |||||||||
| Baseline | 1.55 ± 0.06 | 1.50 ± 0.06 | 1.41 ± 0.09 | 1.61 ± 0.13 | |||||
| End | 1.60 ± 0.06 | 1.52 ± 0.07 | 1.43 ± 0.09 | 1.43 ± 0.08 | 0.933 | −0.06 ± 0.07 | 0.390 | −0.12 ± 0.07 | 0.081 |
| PV ‘a’ rev (m/s) | |||||||||
| Baseline | 0.33 ± 0.01 | 0.33 ± 0.01 | 0.31 ± 0.01 | 0.33 ± 0.01 | |||||
| End | 0.32 ± 0.01 | 0.32 ± 0.01 | 0.33 ± 0.01 | 0.34 ± 0.01 | 0.785 | 0.00 ± 0.01 | 0.457 | 0.02 ± 0.01 | 0.009 |
| LVEF (%) | |||||||||
| Baseline | 63.2 ± 0.9 | 61.6 ± 1.0 | 64.6 ± 0.9 | 63.3 ± 1.2 | |||||
| End | 64.1 ± 0.8 | 62.6 ± 1.2 | 64.6 ± 1.1 | 62.4 ± 0.8 | 0.615 | 0.0 ± 0.8 | 0.961 | 1.3 ± 0.8 | 0.102 |
| S′ (cm/s) | |||||||||
| Baseline | 8.8 ± 0.2 | 9.4 ± 0.3 | 9.4 ± 0.3 | 8.7 ± 0.3 | |||||
| End | 9.1 ± 0.2 | 9.3 ± 0.4 | 9.8 ± 0.4 | 8.6 ± 0.3 | 0.417 | −0.5 ± 0.3 | 0.071 | 0.0 ± 0.3 | 0.914 |
| LAV/BSA (ml/m2) | |||||||||
| Baseline | 30.4 ± 1.3 | 32.4 ± 1.8 | 31.3 ± 1.8 | 35.9 ± 2.5 | |||||
| End | 32.4 ± 1.5 | 33.9 ± 1.8 | 31.7 ± 1.5 | 36.4 ± 2.6 | 0.649 | 0.4 ± 1.0 | 0.693 | −1.0 ± 1.0 | 0.335 |
| LVM/BSA (g/m2) | |||||||||
| Baseline | 92.5 ± 3.8 | 101.5 ± 4.2 | 94.8 ± 3.5 | 90.1 ± 3.8 | |||||
| End | 95.0 ± 4.0 | 106.3 ± 4.5 | 95.1 ± 3.1 | 91.2 ± 4.2 | 0.533 | 2.4 ± 1.8 | 0.195 | −3.5 ± 1.8 | 0.059 |
Data are means ± SEM. Main effect vs. placebo, adjusted for baseline and study site (general linear model). BSA, body surface area.